KNOXVILLE, Tenn., Jan. 28 /PRNewswire-FirstCall/ -- CTI Molecular Imaging, Inc. , a leading provider of positron emission tomography (PET) equipment, molecular probes and services, today announced an agreement between its subsidiary PETNET Solutions and the Yerkes National Primate Research Center of Emory University (Yerkes) for collaboration in the research and development of new PET molecular probes.
Yerkes and PETNET will operate a pre-clinical research site at Yerkes' new neuroscience building, scheduled to open this fall. PETNET additionally will locate a production facility at Yerkes to supply PET isotopes for clinical and research needs, including those at the Yerkes Research Center.
"Molecular imaging plays a key role in the discovery and treatment process for diseases such as Alzheimer's and cancer," said Stuart Zola, Ph.D., director of the Yerkes National Primate Research Center. "We are especially advantaged by our collaborating with PETNET because of the company's expertise in the development and application of molecular probes. By using PET technology, together with nonhuman primate animal models, we can identify earlier and more accurately the pharmacological affects of the compounds we test, thereby clarifying their potential use in diagnosis, treatment and monitoring in humans. Collaboration with PETNET in our basic research and drug-discovery process places Yerkes among a select group of research centers conducting such cutting-edge research. PET results will become a standard used in the drug trial process," Dr. Zola continued.
"Yerkes is one of the preeminent research organizations in the world," said Thomas Hook, President of CTI Solutions. "We are extremely pleased to work closely with them in the development of new molecular probes for PET. With our strategy at PETNET to develop new proprietary molecular probes, this initiative with Yerkes will augment our existing R&D pipeline as well as accelerate the use of molecular imaging in basic research and drug discovery."
"Our collaboration with Yerkes is additional validation that PET will be an extremely valuable tool in the drug discovery processes of the future," continued Hook. "We see this market as a very attractive growth opportunity that will extend the use of PET well beyond today's clinical uses."
CTI Molecular Imaging, Inc. is a leading supplier of products and services for positron emission tomography (PET), a diagnostic imaging technology used in the detection and treatment of cancer, cardiac disease and neurological disorders. Additional information is available at: http://www.ctimi.com/ .
The Yerkes National Primate Research Center of Emory University is one of eight national primate research centers funded by the National Institutes of Health. The Yerkes Center is a multidisciplinary research institute recognized as a leader in biomedical and behavioral studies with nonhuman primates. Yerkes scientists are on the forefront of developing vaccines for AIDS and malaria, and treatments for cocaine addiction and Parkinson's disease. Other research programs include cognitive development and decline, childhood visual defects, organ transplantation, the behavioral effects of hormone replacement therapy and social behaviors of primates. Leading researchers located worldwide seek to collaborate with Yerkes scientists.
About PET and PET/CT:
PET images the biology of diseases at the molecular level, often before changes are visible by anatomical imaging or, in many cases, before symptoms appear. Diseases are biological processes and it is these processes that PET examines. PET/CT is a new imaging technology that combines the biological examination of patients by PET with the CT images of the body's structural detail. PET/CT technology improves the diagnostic accuracy and treatment management of patients by providing surgeons, radiation oncologists and other physicians precise anatomical landmarks associated with the disease condition as determined by PET.
PET's whole-body imaging capability helps physicians improve their ability to detect and determine the location, extent and stage of cancer, neurological disorders and cardiac disease. By improving diagnosis, PET scans aid physicians in selecting better courses of treatment, as well as assessing whether treatment is effective or should be changed. Recent published clinical trials have shown that in a wide array of cancers, the use of PET has caused the treatment to be changed for 15 to 50% of patients, depending on the specific clinical question. In addition, PET and PET/CT provide both the patient and their physician with a degree of certainty that is often unavailable through other imaging methods.
Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as "believe," "assume," "expect," "anticipate," "intend," "estimate" or similar expressions, and any other statements that necessarily depend on future events. Forward-looking statements involve a number of risks and uncertainties and there can be no assurance that any forward-looking statements will prove to be accurate. Various factors could cause actual results to differ materially from those anticipated in the forward-looking statements. CTI undertakes no obligation to update or revise any forward- looking statements. Further information regarding risks, uncertainties and other factors that could adversely affect CTI or cause actual results to differ materially from those anticipated in forward-looking statements are included in CTI's Annual Report on Form 10-K for the fiscal year ended September 30, 2003, Quarterly Reports on Form 10-Q, and in other reports CTI files with the SEC.
CTI Molecular Imaging, Inc.